Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia
Autore:
Wright, P; Birkett, M; David, SR; Meehan, K; Ferchland, I; Alaka, KJ; Saunders, JC; Krueger, J; Bradley, P; San, L; Bernardo, M; Reinstein, M; Breier, A;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co Indianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA River Edge Hosp, Forest Pk, IL USA River Edge Hosp Forest Pk IL USARiver Edge Hosp, Forest Pk, IL USA Hosp Clin & Prov, Barcelona, Spain Hosp Clin & Prov Barcelona SpainHosp Clin & Prov, Barcelona, Spain Hosp Benito Menni, Barcelona, Spain Hosp Benito Menni Barcelona SpainHosp Benito Menni, Barcelona, Spain Univ London, Inst Psychiat, London, England Univ London London EnglandUniv London, Inst Psychiat, London, England
Titolo Testata:
AMERICAN JOURNAL OF PSYCHIATRY
fascicolo: 7, volume: 158, anno: 2001,
pagine: 1149 - 1151
SICI:
0002-953X(200107)158:7<1149:DPCOIO>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPSYCHOTIC-DRUGS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Life Sciences
Citazioni:
8
Recensione:
Indirizzi per estratti:
Indirizzo: Breier, A Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, DC 1748, Indianapolis, IN 46285 USA Eli Lilly & Co DC 1748 Indianapolis IN USA 46285 s, IN 46285 USA
Citazione:
P. Wright et al., "Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia", AM J PSYCHI, 158(7), 2001, pp. 1149-1151

Abstract

Objective: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. Method: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. Results: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7% of those who were treated with intramuscular haloperidol. No significant QT(c) interval changes were observed in any patients. Conclusions: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 07:53:55